Merle (Menachem) Fromer, PhD
img_Merle (menachem) Fromer
ASSOCIATE PROFESSOR | Genetics and Genomic Sciences
Research Topics
Bioinformatics, Gene Discovery, Gene Expressions, Genetics, Genomics
Multi-Disciplinary Training Area
Cancer Biology [CAB], Disease Mechanisms and Therapeutics (DMT), Neuroscience [NEU]
The current focus of Menachem’s research is in developing computational tools to analyze (exome) sequencing data of large samples of thousands of schizophrenia patients in order to uncover genetic variation, in particular structural variation. His main projects include detecting copy number variation (XHMM software) from exome resequecing data, in addition to sequencing-based phasing of haplotype information. Furthermore, he is studying schizophrenia trios (proband and parents) that are being exome sequenced to discover de novo coding mutations ranging from single-nucleotide variants, insertions/deletions, and copy number variation.  He is also collaborating with a number of researchers on developing novel tools for integrating genetic findings into known biological pathways and other functional data, for example, protein-protein interaction networks and protein family and domain information.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Fromer has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.